One in five ischemic stroke survivors will have another stroke within 5 years
Did you know that despite guideline-recommend antiplatelet therapy, the 1-year recurrence rate after an ischemic stroke ranges from 5.7% to 17.7%, and, at 5 years, increases to 14–26%?
Recurrence of ischemic stroke significally increases the risk of death
While secondary prevention strategies have improved recurrence rates, too many of your patients are vulnerable, and death from recurrent stroke remains high.


Recurrent and more severe ischemic strokes tend to be more disabling and increase the risk of dementia
Survivors with higher disability scores after an ischemic stroke are also more likely to suffer subsequent strokes and major cardiovascular events.

Age, race, and socioeconomic factors affect the rates of stroke recurrence
Do you know that the risk of secondary stroke increases in marginalized groups, who may suffer disproportionately from healthcare inequity? Older people, Black adults, and those of low socioeconomic status all have an increased risk of suffering a second stroke.
According to an observational study (N=3816) in Cincinnati, for example, socioeconomic and health inequities likely contributed to higher risk of recurrent stroke in Black adults.
Regional incidence of ischemic stroke and stroke recurrence
While stroke and stroke recurrence remain a global issue, studies investigating the incidence and effects of stroke show striking country variations.
For example, did you know that in Finland, recurrent ischemic stroke increases the risk of death by as much as 16.7-fold (N=970, p=0.005)? Or that in the USA, the incidence of ischemic stroke is as high as 87%, and is associated with a steep increase in disability after the stroke?

Unmet needs, unseen risks
Stroke is the second leading cause of death globally. For survivors, the impact on every day life can be severe. Despite adherence to guideline recommendations for stroke prevention, a significant proportion of survivors experience another stroke.
- Referencesexpand_less
- 1Kolmos M, et al. J Stroke Cerebrovasc Dis. 2021;30(8):105935.
- 2Chen C, et al. Ann Neurol. 2024;96:332–342.
- 3Skajaa N, et al. Neurol. 2022;98(4):e329-e342.
- 4Khanevski AN, et al. Acta Neurol Scand. 2019;140(1):3–8.
- 5Koton S, et al. JAMA Neurol. 2022;79(3):271–280.
- 6Hobenau C, et al. Lancet Neurol. 2022;21(10):889–898.
- 7de Havenon A, et al. JAMA Netw Open. 2024;7(7):e2423677.
- 8Du J, et al. J Am Heart Assoc. 2024;13(3):e030702.
- 9Park JH, et al. Eur J Neurol. 2016;23(2):361–367.
- 10Flach C, et al. Stroke. 2020;51(8):2435–2444.
- 11Albright KC, et al. Neurology. 2018;91(19):e1741–e1750.
- 12Becker CJ, et al. Neurology. 2024;102(11):e209423.
- 13Pennlert J, et al. Stroke. 2017;48(6)1518–1523.
- 14Robinson DJ, et al. Neurology. 2022;99(22):e2464–e2473.
- 15Aarnio K, et al. Stroke. 2014;45(9):2670–2676.
- 16Tsao CW, et al. Circulation. 2023;147:e93–e621.
- 17Dhamoon MS, et al. JAMA Neurol. 207;74(12):1439–1445.
- 18Feigin VL, et al. Lancet Neurol. 2024;23(10):973–1003.
- 19Feigin VL, et al. Lancet Neurol. 2023;22:1160–1206.
- 20Feigin VL, et al. Lancet Neurol. 2021;20(10):795–820.